Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis

Sijia Liu1,2, Román González-Prieto1, Mengdi Zhang3, Paul P. Geurink1,2, Raymond Kooij1,2, Prasanna Vasudevan Iyengar1,2, Maarten van Dinther1,2, Erik Bos1, Xiaobing Zhang4, Sylvia E. Le Dédé4, Bob van de Water4, Roman I. Koning1, Hong-Jian Zhu5, Wilma E. Mesker6, Alfred C.O. Vertegaal1, Huib Ovaal1, Long Zhang5, John W.M. Martens1, and Peter ten Dijke1,2

ABSTRACT

Purpose: Therapies directed to specific molecular targets are still unmet for patients with triple-negative breast cancer (TNBC). Deubiquitinases (DUB) are emerging drug targets. The identification of highly active DUBs in TNBC may lead to novel therapies.

Experimental Design: Using DUB activity probes, we profiled global DUB activities in 52 breast cancer cell lines and 52 patients’ tumor tissues. To validate our findings in vivo, we employed both zebrafish and murine breast cancer xenograft models. Cellular and molecular mechanisms were elucidated using in vivo and in vitro biochemical methods. A specific inhibitor was synthesized, and its biochemical and biological functions were assessed in a range of assays. Finally, we used patient sera samples to investigate clinical correlations.

Results: Two DUB activity profiling approaches identified UCHL1 as being highly active in TNBC cell lines and aggressive tumors. Functionally, UCHL1 promoted metastasis in zebrafish and murine breast cancer xenograft models. Mechanistically, UCHL1 facilitates TGFβ signaling–induced metastasis by protecting TGFβ type I receptor and SMAD2 from ubiquitination. We found that these responses are potently suppressed by the specific UCHL1 inhibitor, 6RK73. Furthermore, UCHL1 levels were significantly increased in sera of patients with TNBC, and highly enriched in sera exosomes as well as TNBC cell–conditioned media. UCHL1–enriched exosomes stimulated breast cancer migration and extravasation, suggesting that UCHL1 may act in a paracrine manner to promote tumor progression.

Conclusions: Our DUB activity profiling identified UCHL1 as a candidate oncoprotein that promotes TGFβ-induced breast cancer metastasis and may provide a potential target for TNBC treatment.

Introduction

Breast cancer is the most frequently diagnosed cancer in women (1), and approximately 90% of breast cancer–related deaths are due to metastasis (2). During the metastasis process, epithelial–mesenchymal transition (EMT) plays an important role, which can be induced by the secreted cytokine TGFβ (3). In the late stage of tumorigenesis, TGFβ stimulates cell invasion and modifies the microenvironment to promote cancer cell intravasation into nearby vessels, and stimulate extravasation into distant tissues and forming of tumor-initiating seeds (4). Increasing evidence indicates that tumor cell–derived exosomes can profoundly influence the tumor local and systemic environment by transferring oncogenic cargo molecules (including protein, RNAs, and lipids) to stromal or less aggressive tumor cells (5). Proteins that are enriched in circulating exosomes can be readily isolated from blood of patients with cancer and have been used as blood-based diagnostic and prognostic markers (6). Once metastasis has been triggered, current treatments frequently fail to provide durable responses (7). Therefore, an improved understanding of the underlying molecular and cellular mechanisms of metastasis is needed to better prevent and treat metastatic breast cancer.

As a highly heterogeneous disease, breast cancer can be classified into multiple subtypes with distinct metastatic potential based on genetic and clinical features (8). For instance, basal-like breast cancers are more aggressive than luminal and normal-like breast cancers (9), and estrogen receptor (ER)–negative tumors are more aggressive than ER–positive ones (10). The most aggressive subtype of breast cancer is triple-negative breast cancer (TNBC), which is defined as lacking expression of ER, progesterone receptor, and HER2. The TNBC subtype accounts for approximately 12% to 17% of breast cancers (11). TNBC remains the most challenging subtype of breast cancer to treat due to a low response rate to chemotherapy and lack of clinically meaningful molecular targets (12). Thus, there is an unmet need for new molecular targets and effective drugs against these novel targets.

Posttranslational modification of proteins by ubiquitination is emerging as a key regulatory mechanism in cell biology for regulating protein degradation and signaling activity (13). Ubiquitination is mediated by ubiquitin E3 ligase enzymes and reverted by deubiquitinases (DUB). About 100 human DUBs have been identified, and some of them play important roles in cancer progression (14). The...
Translational Relevance

Metastasis is the leading cause of breast cancer-associated death. Triple-negative breast cancer remains the most challenging subtype to treat. Deubiquitinases (DUB) are emerging drug targets in cancer treatment. To discover new DUB targets, we profiled global DUB activities in 52 human breast cancer cell lines and 52 patients’ tumor tissue samples. Two independent DUB activity profiling approaches identified UCHL1 as being highly active in TNBC cell lines and aggressive tumors. Mechanistically, UCHL1 facilitates TGFβ signaling–induced metastasis by restricting ubiquitination of TGFβ type I receptor and its downstream effector, SMAD2. We further found that UCHL1 covalent activity inhibitor 6RK73 can be used as a potential drug to specifically inhibit UCHL1 activity in breast cancer. Furthermore, we observed that sera of patients with TNBC contain high UCHL1 levels, which may represent a blood-based biomarker for early diagnosis of metastasis. In sum, our study has identified UCHL1 as a potential target for TNBC treatment.

Materials and Methods

Ethics statement and preparation of clinical samples

ER-positive and -negative fresh-frozen tumor tissues and sera were randomly selected from the historical tumor biobank at the Erasmus MC Cancer Institute. Use of biospecimen for biomarker research has been approved by the Medical Ethics Committee of the Erasmus MC and was performed in accordance to the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (http://www.federa.org/). Sera samples from 10 patients with TNBC were selected that had no prior treatment, and sera from 25 volunteers were selected as controls. Sera samples from TNBC and controls were stored at −80°C.

Cell lines and cell culture

HEK293T and A549 cells were originally obtained from the American Type Culture Collection and cultured in DMEM supplemented with 10% FBS and 100 U/mL penicillin–streptomycin (15140122; Gibco). The 52 breast cancer cell lines that were used in this study were cultured in Roswell Park Memorial Institute medium (11875093; Gibco) supplemented with 10% FBS and 100 IU/mL penicillin–streptomycin. All the 52 breast cancer cell lines were molecularly and biochemically characterized and are listed in Supplementary Table S1. All the cells were routinely tested for absence mycoplasma contamination and checked for authenticity by short tandem repeat profiling.

Zebrafish extravasation assay of human breast cancer cells

Transgenic zebrafish lines Tg (fltl:EGFP) were raised according to standard procedures in compliance with the local Institutional Committee for Animal Welfare of the Leiden University. Zebrafish extravasation assays were prepared as previously described (21). Zebrafish were fixed with 4% paraformaldehyde 6 days after injection. Imaging and quantification of the results were carried out on an inverted SPS STED confocal microscope (Leica). At least 40 zebrafish were analyzed for each group, and three representative images were taken. All the experiments were repeated at least 3 times, and representative results are shown.

Breast cancer metastasis assay in mice xenograft model

Mice were purchased from the animal husbandry center of the Shanghai Institute Cell Biology, Academia Sinica, Shanghai, China. For the intracardial injection, 5-week-old female BALB/c nude mice were anesthetized with isoflurane, and single-cell suspension of MDA-MB-231 BM Luc (100.000/100 μL PBS) cells or MDA-MB-436 Luc (300.000/100 μL PBS) cells was inoculated into the left heart ventricle according to the method described by Arguello and colleagues (22). Ten mice were injected in each group. Bioluminescent imaging was used to verify successful injection and to monitor the outgrowth of metastasis weekly. Mice experiments were approved by the Zhejiang University Animal Welfare Committee.

6RK73 synthesis

The 6RK73 compound was synthesized according to a reported procedure (23). NMR and analytical LC-MS analysis were performed to confirm the nature and purity of the compound.

Exosome isolation from cell and sera

Exosome isolation was performed as previously described (24, 25). Supernatants from cell and sera samples from patients were concentrated by 100 K NMWL centrifugal filtration (UFC910024; Millipore) at 4°C 10 × 10⁵ g and washed twice with PBS. Exosomes were recovered from the concentrated supernatant by ultracentrifugation at 100 × 10⁵ g for 17 hours at 4°C. Exosome pellets were resuspended in ice-cold PBS at 4°C. The concentration of exosomal proteins was quantified using DC protein assay (Pierce).

Statistical analysis

Statistical analysis was performed using Prism 8 software (GraphPad). Numerical data from triplicates are presented as the mean ± SD, except for analysis of Zebrafish experiments where a
representative result is expressed as mean ± SEM. The significance of differences between two independent subjects was determined using the unpaired Student t test. Two-way ANOVA has been used to analyze multiple subjects. The Kaplan-Meier method was used to evaluate metastasis-free survival of mice between two groups. P values are indicated by asterisks in the figures: *, P < 0.05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001. Differences at P = 0.05 and lower were considered significant.

See Supplementary Information for additional descriptions regarding methods that were used.

Results

DUB activity profiling identified UCHL1 as a highly active DUB in aggressive breast cancer

We first established a workflow to systematically determine the differential DUB activities in 52 human breast cancer cell lines and 52 tumor tissues of patients with breast cancer by using TAMRA-ubiquitin-VME, which is a ubiquitin-based activity probe for cysteine DUBs labeled on the N-terminus with a 5-carboxytetramethylrhodamine (TAMRA) dye and equipped with a reactive C-terminal vinyl methyl ester (VME) warhead (Fig. 1A). Among all the bands that were labeled with TAMRA ABP and visualized by fluorescence scanning, a band on the bottom of the gel displayed large variation in intensity levels between cell lines with representatives for Basal A, Basal B, Luminal, and Luminal HER2 subtypes (Fig. 1B). To identify the DUB corresponding to this band, we used Biotin-ubiquitin-VME ABP to pull down the protein and identified it by LC/MS-MS (Fig. 1C). We performed the DUB identification in MDA-MB-436 cells, which showed strong intensity of the band of interest in the TAMRA and Biotin ABP result (Fig. 1D). The LC/MS-MS identified the DUB as UCHL1, and the Biotin-ubiquitin-VME ABPs were also identified and almost equally enriched with UCHL1 in the samples (Fig. 1E; Supplementary Fig. S1A). Next, we measured the intensities of the UCHL1-corresponding band in the TAMRA ABP profiling results by densitometry to compare UCHL1-corresponding activities between different breast cancer subtypes (Supplementary Table S1); UCHL1 activities were significantly increased in TNBC lines compared with non–TNBC cell lines (Fig. 1F). Next, DUB activity profiling with TAMRA ABP was performed in 26 ER+ and 26 ER− breast cancer patient tumor tissues (Supplementary Fig. S1B), and UCHL1-corresponding activities in ER+ patient tumors were significantly higher than the activities in ER− patient tumors (Fig. 1G; Supplementary Table S2).

The second parallel DUB activity profiling was performed with Biotin-ubiquitin-VME ABP combined with LC/MS-MS analysis in 20 randomly picked Basal and Luminal human breast cancer cell lines (Fig. 2A; Supplementary Table S3). All the targets identified by LC/MS-MS were plotted by hierarchical clustering to compare biological replicates (Fig. 2B). Average label-free quantification log2 difference between Basal and Luminal, ER+ and ER−, and TNBC and non–TNBC subtype cell lines revealed that UCHL1 activity was highly enriched in Basal, ER-negative, and TNBC subgroups (Fig. 2C; Supplementary Table S4). To further validate the Biotin ABP profiling result of UCHL1, we compared UCHL1 activity detected by Biotin ABP and TAMRA ABP profiling with the UCHL1 protein level measured by Western blot (WB) in these 20 breast cancer cell lines (Fig. 2D). Both profiling results of UCHL1 activity showed similar results, and the UCHL1 protein level detected by WB was found to be a major determinant for UCHL1 activity level (Fig. 2D). Taken together, both DUB activity profiling methods identified UCHL1 as being highly activated in aggressive breast cancer.

UCHL1 promotes breast cancer metastasis in xenograft models

To explore the role of UCHL1 activity in breast cancer metastasis, we first analyzed the effect of its misexpression in breast cancer cells on extravasation in a zebrafish breast cancer xenograft model (Fig. 3A). First, we overexpressed UCHL1 in mCherry-expressing MDA-MB-231 cells, which has a low endogenous UCHL1 expression/activity level as determined by WB and TAMRA ABP assays (Fig. 3B; Supplementary Fig. S2A). Injection of the same number of cells into the circulation of zebrafish embryos revealed after 6 days significantly increased number of invasive cells in the UCHL1-Flag group compared with the vector control group (Fig. 3C and D). The proliferation of both cell lines when grown on plastic showed no significant difference (Supplementary Fig. S2B). Next, we knocked down UCHL1 in mCherry-expressing MDA-MB-436 cells, which have high endogenous UCHL1 expression/activity level by using two independents short hairpin RNAs (shRNA). The knockdown efficiency was validated by WB and TAMRA ABP assays (Fig. 3E; Supplementary Fig. S2C). The UCHL1 knockdown groups revealed not only less invasive cells but also a weaker metastatic phenotype (cells were unable to extravasate into zebrafish tail fin and formed clusters in between the blood vessels) compared with a nontargeting (NT) shRNA and empty vector (PLKO) control groups (Fig. 3F and G). The proliferation was not affected by UCHL1 depletion (Supplementary Fig. S2D).

Next, to further confirm that UCHL1 promotes breast cancer metastasis, we used a mouse breast cancer xenograft model in which we intracardially injected breast cancer cells stably expressing firefly luciferase, into female BALB/c athymic nude mice. Bioluminescent images (BLI) were taken every week to monitor colonization in different organs after successful injection (Fig. 3H). UCHL1-overexpressing MDA-MB-231 cells exhibited significantly increased metastasis in different organs 35 days after injection (Fig. 3I and K) and shorter metastasis-free survival periods than the empty-vector control group (Fig. 3J). Furthermore, nude mice were intracardially injected with luciferase-labeled PLKO control and sh1-UCHL1 knockdown MDA-MB-436 cells. The PLKO group showed metastasis in different organs at 49 days after injection (Fig. 3L and N), and shorter metastasis-free survival periods than sh1-UCHL1 group (Fig. 3M). Altogether, the mice and zebrafish results confirm that UCHL1 promotes breast cancer invasion and metastasis.

UCHL1 facilitates TGFβ signaling–induced TNBC migration and extravasation by protecting TßRI and SMAD2 from ubiquitination

Next, we investigated the underlying mechanism by which UCHL1 promoted breast cancer metastasis. Because EMT plays an important role during breast cancer metastasis (3), we firstly tested the effect of UCHL1 depletion in MDA-MB-436 cells on the levels of several mesenchymal markers. Knockdown of UCHL1 significantly decreased VIMENTIN, SNAIL, and SLUG expression both at the RNA and protein levels (Fig. 4A and B). In addition, qPCR results showed a modest decrease of β-CATENIN, ZEB1, and ZEB2 expression upon UCHL1 depletion (Supplementary Fig. S3A). Because TGFβ is a key activator of EMT, we next examined whether UCHL1 can control TGFβ signaling. Indeed, ectopic expression of UCHL1 in MDA-MB-231 cells (low endogenous UCHL1 activity) promoted TGFβ-induced pSMAD2 levels, and this coincided with increased TGFβ type I receptor (TßRI) and SMAD2 levels (Fig. 4C). Knockdown of UCHL1 in MDA-MB-436 cells (high endogenous UCHL1 activity) suppressed pSMAD2, TßRI, and SMAD2 levels (Fig. 4D). Besides, ectopic expression of UCHL1 in HEK293T cells upregulated the TGFβ-induced SMAD3/4-driven transcriptional CAGA12-luc response,
UCHL1 Promotes TGFβ-Induced Breast Cancer Metastasis

Figure 1.
DUB activity profiling identified UCHL1 as being selectively highly activated in aggressive breast cancer tumor tissues and cell lines. A, Schematic overview of DUB activity profiling with TAMRA ABP and Biotin ABP assay in MDA-MB-436 cells. B, Atlas of DUB activity in 52 breast cancer cell lines. Four gels were merged together with dashed line in between two gels. C, DUB identification workflow with Biotin ABP. D, TAMRA ABP and Biotin ABP assay in MDA-MB-436 cells. E, LC-MS/MS analysis of in-gel tryptic digestion of excised gel slice indicated in Fig. 1D. F, UCHL1 activity analysis of 52 breast cancer cell lines. **, P < 0.01, unpaired Student t test. G, UCHL1 activity analysis of 52 tissues from patients with breast cancer. ***, P < 0.001, unpaired Student t test.
Figure 2.
Quantitative DUB activity–based proteomic profiling identified UCHL1 as being selectively highly active in TNBC cell lines. A, Schematic overview of quantitative DUB activity profiling with Biotin ABP. B, Heatmap depicting sample clustering considering Z-score of proteins identified by LC-MS/MS after Biotin-ABP profiling. The tree indicates Euclidean distances between samples. C, Scatterplots depicting statistical differences between cell lines grouped by tumor subtype. A filled dot indicates that a protein is statistically significantly different between any of the groups of study and the control sample set. An empty dot indicates that there is no statistically significant difference between any of the groups of study and the control sample group. Location of UCHL1 is marked with a circle. D, Biotin ABP, TAMRA ABP, and WB analysis of UCHL1 in 20 breast cancer cell lines, and TNBC cell lines were highlighted with red color. Two blots were merged together with a gray line in between two blots. Same blot was used for UCHL1 and Tubulin (loading control).
Figure 3.
UCHL1 promotes breast cancer metastasis in zebrafish and mice xenograft models. A, Workflow of breast cancer extravasation experiment in a zebrafish model. The blood vessels and cancer cells are fluorescently labeled in green and red, respectively. B, UCHL1-overexpressing and control vector–expressing MDA-MB-231 cell lines were established and validated by WB. Same blot was used for UCHL1 and Tubulin (loading control). C, Analysis of invasive cell numbers of control and UCHL1 groups in zebrafish metastasis experiment. ****, P < 0.0001, unpaired Student t test. D, Representative images of zebrafish from the control and the UCHL1 group with zoom-in of invasive cells on the right plot. E, Two UCHL1 shRNA knockdown MDA-MB-436 cell lines and two control cell lines PLKO (empty vector) and NT were established and validated by WB. Same blot was used for UCHL1 and Tubulin (loading control). F, Analysis of invasive cell numbers of each group in zebrafish metastasis assay. *, P < 0.05; **, P < 0.01; and ****, P < 0.0001, two-way ANOVA. G, Representative images from four groups with zoom-in on the right plot. H, Workflow of breast cancer metastasis experiment in mouse model. I, BLI signal of metastasis of control and UCHL1 overexpression in MDA-MB-231 cells were measured at indicated times. **, P < 0.01, two-way ANOVA. J, Percentage of metastasis-free mice in each group followed in time. *, P < 0.05, log-rank test. K, BLI signal of metastasis of three representative mouse images with both ventral and dorsal sides from each group at day 35 after injection. L, BLI signal of metastasis of PLKO and sh1-UCHL1 MDA-MB-436 cells was measured at indicated times. *, P < 0.05, two-way ANOVA. M, Percentage of metastasis-free mice in each group followed in time. ***, P < 0.001, log-rank test. N, BLI signal of metastasis of three representative mouse images with both ventral and dorsal sides from each group at day 49 after injection.
UCHL1 regulates mesenchymal phenotype of breast cancer cells and promotes TGFβ/SMAD signaling--induced breast cancer extravasation. A, WB analysis of mesenchymal markers in UCHL1 shRNA knockdown MDA-MB-436 cells. Same blot was used for UCHL1, SLUG, and Tubulin (loading control). VIMENTIN and SNAIL were increased in UCHL1 shRNA knockdown MDA-MB-436 cells. **, P < 0.01; ***, P < 0.001, two-way ANOVA. (Continued on the following page.)
whereas knockdown of UCHL1 decreased this effect significantly (Supplementary Fig. S3C). To investigate whether UCHL1 interacts with TßRI, we performed immunoprecipitation (IP) of UCHL1 followed by WB for TßRI using HEK293T cell lysates. We observed that Flag-tagged UCHL1 interacted with both overexpressed and endogenous TßRI upon TGFß treatment (Fig. 4E; Supplementary Fig. S3D). Besides, we found that recombinant UCHL1 preferentially binds to ubiquitinated TßRI. This posttranslational modification of TßRI is triggered by TGFß treatment (Supplementary Fig. S3E). We also found in IP–WB experiments that UCHL1 interacts with SMAD2 in HEK293T cells. This endogenous interaction was not TGFß dependent (Fig. 4E). As UCHL1 is a small protein in which either deletion of N- or C-terminal sequences will result in loss of solubility and misfolding (26), it is not possible to make truncated versions to study the responsible domain of UCHL1 for the interaction with TßRI and SMAD2. We therefore resorted to investigate the effect of specific amino acid mutations in UCHL1 on the interaction of UCHL1 with TßRI or SMAD2. These mutations were previously shown to interfere with UCHL1 DUB function (26, 27). Our results showed that the catalytic triad mutants (C90S, C90A, D176N, H161D, and H161Y), ubiquitin binding mutant (D30K), and double mutant (D30K & D176N) which are defective in DUB activity as measured by TAMRA-ABP assay still interact with TßRI or SMAD2. However, the S18Y mutant of UCHL1 retained DUB activity in TAMRA-ABP assay but demonstrated a decreased interaction with TßRI or SMAD2 (Supplementary Fig. S4A and S4B). These results suggest the N-terminal region in vicinity of Serine 18 in UCHL1 plays an important role in the interaction with TßRI or SMAD2. To further validate and investigate the endogenous interactions and subcellular localization of TßRI-UCHL1 and SMAD2-UCHL1, we performed proximity ligation assays (PLA) in A549 cells. A549 cells were chosen as they contain a large cytoplasm unlike MDA-MB-436 and HEK293T cells; the large cytoplasm facilitates studies on subcellular distribution. Results showed that the interaction between UCHL1 and TßRI occurs in a ligand-dependent manner (Fig. 4F; Supplementary Fig. S3G and S3H). The interaction between UCHL1 and SMAD2 is not ligand dependent, but we found that the subcellular localization of the interaction shifted from cytoplasm to nucleus after TGFß treatment (Fig. 4F; Supplementary Fig. S3F–S3H). Importantly, we found that the interaction between UCHL1 and TßRI occurs in the early endosome. The PLA experiments with TßRI and SMAD2 were analyzed by in vivo IP and showed HEK293T cells treated with 10 µg/mL inhibitor for 6 days after injection, and refreshed every other day. **, P < 0.0001, two-way ANOVA. Representative images from four groups with zoom-in of the tail fin area are shown in the left plot. Analysis of invasive cell number of Control, Control ± SB, UCHL1, and UCHL1 ± SB groups in zebrafish extravasation assay is shown in the right plot.

To investigate whether UCHL1-induced metastasis is dependent on its ability to potentiate TGFß signaling, we employed the selective TßRI/SMAD signaling inhibitor SB431542 (SB) to block TGFß receptor signaling in migration and extravasation assays. In a scratch assay, SB treatment blocked the ability of UCHL1 to promote MDA-MB-231 cell migration (Fig. 4L). Results of the extravasation assay showed that SB also blocked the stimulatory effect of UCHL1 on MDA-MB-231 cell extravasation in an in vivo zebrafish xenograft model (Fig. 4M). Besides, we performed functional rescue experiments. Ectopic expression of TßRI, SMAD2, or SMAD3 mimicked the promoting effect of
Figure 5.
UCHL1 activity inhibitor antagonizes TGFβ signaling and inhibits breast cancer migration and extravasation. **A**, Chemical structure of the selective covalent UCHL1 activity inhibitor 6RK73. **B**, IC₅₀ analysis of 6RK73. **C**, TAMRA ABP analysis of UCHL1-reversible activity inhibitor LDN57444 and covalent activity inhibitor 6RK73 in MDA-MB-436 cells; 5 μmol/L LDN57444 or 6RK73 was added to the cells overnight. TAMRA and Coomassie results were obtained from the same gel. **D**, TAMRA ABP analysis of 6RK73 in 21# patient specimen; 5 μmol/L 6RK73 was added in the lysate for 30 minutes. TAMRA and Coomassie results were obtained from the same gel. **E**, CAGA12-Luc reporter analysis of 6RK73 in HEK293T cells; 5 μmol/L 6RK73 was added to the cells overnight. /C3, P < 0.05, two-way ANOVA. **F**, WB analysis of TβRI, SMAD2, and pSMAD2 in MDA-MB-436 cells treated with or without 5 μmol/L 6RK73 overnight. Same blot was used for UCHL1, pSMAD2, and GAPDH (loading control). TβRI and SMAD2 were obtained from another two blots using the same corresponding cell lysates. **G**, In vitro scratch wound-healing assay of MDA-MB-436 cells treated with and without 5 μmol/L 6RK73 for 48 hours, and time-lapse imaging was performed every hour. Relative wound area was analyzed for each group at indicated times. /C3, P < 0.05; /C3/C3, P < 0.01, two-way ANOVA. **H**, Representative images of cells from DMSO and 6RK73 groups. **I**, In vivo zebrafish extravasation assay of MDA-MB-436 cells, in which the injected zebrafish were treated with or without 6RK73 for 6 days. 6RK73 (5 μmol/L) was added in the egg water and refreshed every other day. Invasive cell number was analyzed for DMSO and 6RK73 groups. *C3/C3/C3/C3, P < 0.0001, unpaired Student t test. **J**, Representative images of zebrafish from DMSO and 6RK73 groups with zoom-in of invasive cells are shown in the right plot.
UCHL1 on migration of MDA-MB-231 cells as measured by real-time imaging system (Supplementary Fig. S5A). In addition, we found that overexpression of TβRI, SMAD2, or SMAD3 partially compensated the inhibitory effect of UCHL1 knockdown in MDA-MB-436 cells in a migration assay (Supplementary Fig. S5B). Altogether, these results demonstrate that UCHL1 facilitates TGFβ signaling–induced TNBC migration and extravasation by protecting TβRI and SMAD2 from ubiquitination. Besides, we found that activity of UCHL1 is required for the metastasis-promoting activity of UCHL1. When we overexpressed C90A catalytically inactive mutant of UCHL1 in MDA-MB-231 cells, UCHL1 lost its promotion function and showed slightly dominant-negative regulation of migration and extravasation (Supplementary Fig. S3C and S3D).

**UCHL1 activity inhibitor antagonizes TGFβ/SMAD signaling and inhibits breast cancer migration and extravasation**

In order to study the effect of UCHL1 activity inhibition on the TGFβ pathway and breast cancer metastasis, we turned to a recently reported panel of UCHL1 inhibitors and decided to synthesize and characterize one of the most potent ones (23). This compound, 6RK3, covalently binds to UCHL1 (Fig. 5A; Supplementary Fig. S6A), showed excellent inhibitory potency toward UCHL1 based on an in vitro IC₅₀ assay and a high selectivity over other DUBs including its closest family members UCHL3 and UCHL5 (Fig. 5B). We examined its effect in living cells, and we took along the reversible competitive UCHL1 inhibitor LDN57444. 6RK3 showed more potent inhibition than LDN57444 on UCHL1 activity in MDA-MB-436 cells by TAMRA ABP assay; the inhibitory efficiency of 6RK3 was comparable to that of a generic knockdown of UCHL1 (Fig. 5C). Next, we used 6RK3 to test its specificity against UCHL1 activity on all the DUBs by performing a TAMRA ABP assay in patient tumor specimen, and only UCHL1 band decreased among all the DUBs detected (Fig. S5D). We can conclude that 6RK3 displays a potent and specific inhibitory effect on UCHL1 both in vitro and in vivo.

To investigate whether 6RK3 can inhibit TGFβ signaling, we performed a CAGA₁₂-Luc reporter transcriptional assay in HEK293T cells. Treating cells with 6RK3 inhibited the TGFβ/SMAD-induced transcriptional response (Fig. 5E). Moreover, 6RK3 treatment of MDA-MB-436 cells displayed strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels; the inhibitory efficiency of 6RK3 was stronger than the effect observed after shRNA-mediated UCHL1 knockdown (Fig. 5F; Supplementary Fig. S6B). Furthermore, we tested the effect of 6RK3 on migration of MDA-MB-436 cells. 6RK3-treated MDA-MB-436 cells migrated significantly slower than the DMSO control group (Fig. 5G and H). To study the function of 6RK3 on breast cancer extravasation, we used the MDA-MB-436 cells injected zebrafish xenograft with DMSO or 6RK3 that was added in the egg surrounding the zebrafish embryos. Extravasation of the cells in 6RK3-treated zebrafish was potently inhibited (Fig. 5I and J). Taken together, 6RK3 showed specific inhibition of UCHL1 activity and TGFβ/SMAD2 and SMAD3 signaling, and potent inhibition of breast cancer migration and extravasation.

**UCHL1** exosomes upregulate TGFβ signaling and serve as blood-based biomarker for aggressive breast cancer

Clinically, UCHL1 has successfully been used as blood biomarker for traumatic brain injury and concussion (28). However, it is unknown whether UCHL1 has a role and/or is present in sera of patients with breast cancer. Therefore, we performed a UCHL1 ELISA on sera samples collected from patients with TNBC and healthy donors. Interestingly, UCHL1 protein levels in the TNBC group are significantly higher as compared with healthy controls (Fig. 6A). In addition, UCHL1 levels are also higher in ER-negative patient sera than in sera from ER-positive cases (Supplementary Fig. S6C). Nevertheless, UCHL1 is not a secreted protein, and this raised the question of how UCHL1 can be found in the blood circulation. A recent study demonstrated that cancer-overexpressed proteins can be packaged in exosomes and enter circulation which is useful for minimally invasive cancer detection (29). We hypothesized that UCHL1 overexpressed in aggressive breast cancer may be secreted via exosomes by cells and that circulated in the blood of patients via exosomes. To further verify this hypothesis, we isolated exosomes from sera of patients with breast cancer by differential ultracentrifugation (24) and found that the total amount of UCHL1 in sera is highly enriched in the isolated exosomes fraction (Fig. 6B). Next, we isolated exosomes from conditioned media of MDA-MB-436 (TNBC) and MCF-7 (non TNBC) cell cultures. ELISA results showed that the UCHL1 levels were higher in exosomes isolated from MDA-MB-436 cells than from MCF-7 cells. Moreover, UCHL1 level significantly decreased in exosomes isolated from MDA-MB-436 cells that were depleted for UCHL1 compared with PLKO cells (Fig. 6C). WB analysis of UCHL1, and that of a common exosomal marker protein Flotillin-1, showed lower UCHL1 levels in MCF7 exosomes than MDA-MB-436 exosomes, and a decreased UCHL1 level in shUCHL1 MDA-MB-436 exosomes (Fig. 6D). Exosomes are extracellular vesicles with a diameter of 50 to 200 nm (30). To further characterize the exosomes, we isolated them from sera and cell conditioned media, and we performed transmission electron microscopy (TEM) imaging to show the shape and size of these purified exosomes and used nanoparticle tracking analysis (NTA) to determine their concentrations and size distributions. Results showed that both sera and cell samples displayed exosome-typical size and morphology by TEM analysis, and were enriched in the size from 100 to 200 nm vesicles by NTA analysis (Fig. 6E). Taken together, UCHL1 levels were significantly increased in sera of patients with TNBC and highly enriched in exosomes from sera of patients bearing aggressive tumors and in TNBC cell–conditioned media.

To further investigate whether UCHL1**⁺** exosomes regulate TGFβ/SMAD signaling, we first tested the effect of the PLKO and shUCHL1 MDA-MB-436 exosomes on the CAGA₁₂-Luc reporter activity in HEK293T cells. Treatment of UCHL1-containing exosomes resulted in higher luciferase signal in HEK293T cells than exosomes in which UCHL1 was depleted (Fig. 6F). Consistent with this finding, the pSMAD2 levels were also increased upon treatment with control exosomes from MDA-MB-436 cells but not by exosomes depleted of UCHL1 as analyzed by WB in MDA-MB-436 cells with UCHL1 knockdown (Fig. 6G). To further validate these results, we labeled the exosomes that were isolated from PLKO and shUCHL1 MDA-MB-436 cells with a fluorescent lipid dye (PKH67), and thereafter added them to MDA-MB-436 cells with UCHL1 knockdown. After the exosomes were taken up by the cells, we performed immunofluorescent staining of pSMAD2. Confocal microscopy imaging revealed that the pSMAD2 levels were higher in the cells which were treated with PLKO MDA-MB-436 cell exosomes than shUCHL1 MDA-MB-436 cell exosomes (Fig. 6H; for an enlarged view, see Supplementary Fig. S6D). To further evaluate the biological function of UCHL1**⁺** exosomes, we examined their effect on the migration of MDA-MB-436 cells with UCHL1 knockdown. Cells treated with PLKO MDA-MB-436 exosomes migrated more than exosomes depleted for UCHL1 (Fig. 6I and J). The potential function of UCHL1**⁺** exosomes was further validated in a zebrafish xenograft model by injecting MDA-MB-436 cells with UCHL1 knockdown. The cells pretreated with
**Figure 6.**
UCHL1+ exosomes upregulate TGFβ signaling and serve as blood-based biomarker for aggressive breast cancer. **A,** ELISA analysis of UCHL1 levels in serum samples from healthy donors and patients with TNBC. **B,** ELISA analysis of UCHL1 level in serum and relative exosomes from 6 patients with breast cancer. **C,** ELISA analysis of UCHL1 level in exosomes from breast cancer cell lines. **D,** WB analysis of exosome markers Flotillin-1 and UCHL1 in exosomes from four breast cancer cell lines. Same blot was used for UCHL1 and Flotillin-1 (loading control). (Continued on the following page.)
PLKO MDA-MB-436 exosome showed more invasion and stronger extravasation phenotype than the cells pretreated with shUCHL1 MDA-MB-436 exosome (Fig. 6K and L). Taken together, donor cells highly active for UCHL1 can upregulate TGFB/SMAD signaling in recipient cells via exosome transfer and promote their migration and extravasation.

Discussion

Large-scale conventional genomic and proteomic profiling has been performed in breast cancer (31), and a growing numbers of DUBs have been uncovered to be aberrantly expressed in breast cancer (32). However, there is still very little knowledge on the overall activities of DUBs in breast cancer. Thus, we performed activity profiling studies using ABPs on DUBs in human breast cancer cell lines and patient tumor tissues to study its activity-related biological function in different subtypes of breast cancer. UCHL1 was identified as the most specific highly active DUB in the TNBC subtype, and targeting of its activity mitigated TNBC cell migration and metastasis.

In this work, two different ABP-based DUB activity profiling methods were performed. Each profiling method has its own advantages and drawbacks. The TAMRA ABP profiling method is a simple, fast, and convenient method, which allows us to achieve a snapshot of the DUB activity landscape with a very small amount of protein, whereas the Biotin ABP profiling coupled to mass spectrometry analysis method is a more laborious requiring a larger amount of protein, but enables the identification of the DUBs in a quantitative manner. Both DUB activity profiling methods identified UCHL1 as the most specific highly active DUB in the TNBC subtype. In the Biotin ABP profiling, other DUBs such as USP4 were previously reported to promote breast cancer metastasis that were detected in the Biotin ABP profiling to be highly active in TNBC group (33). OTUD3 that displayed selective high activity in non-TNBC was found formerly to act as a suppressor in breast cancer tumorigenesis and metastasis (ref. 34; Fig. 2C). There are some other interesting hits for which still little is known about their function in breast cancer that can be studied in the future (Supplementary Tables S3 and S4). Although there are several reports that UCHL1 may possibly act as a tumor suppressor in breast cancer pathogenesis, most evidence supports its role as a positive regulator of tumorigenesis (35, 36). These differences may be attributed to differential action of UCHL1 in different breast cancer subtypes.

Functionally, we observed that UCHL1 promoted breast cancer migration, extravasation, and metastasis both in zebrafish and mice xenograft models. Mechanistically, UCHL1 facilitates TGFB/SMAD2 and SMAD3 signaling and TGFB-induced TNBC migration and extravasation by protecting TβRI and SMAD2/3 from ubiquitination. Next, we found that UCHL1 mainly regulates lysine 48-linked ubiquitination of TβRI and SMAD2/3 (Supplementary Fig. S4E–S4G). The interaction of TβRI with UCHL1 was found to be ligand-dependent. UCHL1 interacted more efficiently with ubiquitylated TβRI, and TGFB triggers the ubiquitination of TβRI. The latter may thus contribute to the ligand-induced interaction between TβRI and UCHL1. The interaction between UCHL1 and TβRI occurs in early endosomes, where activated TGFB receptor complexes promote SMAD-dependent signaling responses (37). Although our results point to a pivotal role for UCHL1 in stimulating breast cancer extravasation by regulating TGFB signaling, we do not preclude that UCHL1 may also promote invasion and metastasis by targeting other signaling proteins. Previous studies showed that UCHL1 can also regulate protein kinase B (AKT) and hypoxia-inducible factor 1α (HIF1α) signaling (36, 38). However, upon shRNA-mediated knockdown in MDA-MB-436 cells, we were unable to detect changes in AKT and HIF1α protein levels (Supplementary Fig. S3B), suggesting a context-dependent role for UCHL1 in controlling substrate proteins.

When comparing the UCHL1 inhibitor LDN57444 with 6RK73, LDN57444 is a reversible and competitive inhibitor of UCHL1 activity (IC₅₀ = 0.88 μmol/L; ref. 39), whereas 6RK73 is a covalent irreversible inhibitor of UCHL1 activity (IC₅₀ = 0.23 μmol/L; Fig. 5B, Supplementary Fig. S6A). LDN57444 also inhibits UCHL3 activity (IC₅₀ = 25 μmol/L; ref. 39), whereas 6RK73 showed almost no inhibition of UCHL3 (IC₅₀ = 236 μmol/L; Fig. 5B). Besides, 6RK73 displayed a potent inhibition of breast cancer extravasation in zebrafish (Fig. 5I and J), and this result is reminiscent to the inhibitory effect observed upon genetic UCHL1 depletion (Fig. 3F and J). Clinically, high UCHL1 expression is also associated with many other types of cancers including lung, colorectal, and pancreatic (40). Thus, 6RK73 may provide a new choice for the development of a clinical drug for targeting UCHL1 activity in the treatment of aggressive breast cancer and other UCHL1 overactive cancers.

In addition, UCHL1 was found to be highly enriched in sera of patients with TNBC compared with samples from healthy individuals. More importantly, we found that UCHL1 was specifically enriched in exosomes from sera of patients with aggressive breast cancer and TNBC cell-conditioned medium. In this respect, our finding that UCHL1 and TβRI colocalize in early endosomes is of interest as early endosomes are precursor vesicles for exosomes (41). Another group, also recently detected UCHL1 in the exosomes of sera of patients with breast cancer, and high UCHL1 levels were found to be correlated with chemotheraphy resistance phenotype (42). We found that UCHL1+ exosomes upregulated TGFB/SMAD signaling and promoted migration and extravasation of the recipient breast cancer cells. This suggests that UCHL1 may act in cancer cells in both cell autonomous and paracrine manners to stimulate tumorigenesis.

Altogether, our results demonstrate the important roles for UCHL1 in breast cancer migration and extravasation by upregulating TGFB signaling and highlight a potential novel therapy for cancer treatment by targeting UCHL1. UCHL1-containing exosomes also have the potential to be a blood-based biomarker for early diagnosis of
aggressive breast cancer. The selective, potent, and covalent UCHL1 activity inhibitor 6RK73 may open new avenues for therapeutic intervention in breast cancer and beyond.

Disclosure of Potential Conflicts of Interest

H. Ovaas holds ownership interest (including patents) in UbiQ Bio V.O.F. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: S. Liu, H.-J. Zhu, P. ten Dijke
Development of methodology: S. Liu, P. ten Dijke
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Liu, R. Gonzalez-Prieto, M. Zhang, P.P. Geurink, R. Kooij, P.V. Iyengar, M. van Dinhier, E. Bos, X. Zhang, S.E. Le Dévédec, B. van de Water, H. Ovaas, J.W.M. Martens
Analysis and interpretation of data (e.g., statistical analysis, biosistics, computational analysis): S. Liu, R. Gonzalez-Prieto, M. Zhang, P.P. Geurink, R. Kooij, P.V. Iyengar, R.I. Koning, H.-J. Zhu, J.W.M. Martens, P. ten Dijke
Writing, review, and/or revision of the manuscript: S. Liu, R. Gonzalez-Prieto, P.P. Geurink, P.V. Iyengar, S.E. Le Dévédec, B. van de Water, H.-J. Zhu, W.E. Mesker, A.C.O. Vertegaal, H. Ovaas, J.W.M. Martens, P. ten Dijke
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Liu, W.E. Mesker, L. Zhang, P. ten Dijke
Study supervision: S. Liu, H.-J. Zhu, W.E. Mesker, H. Ovaas, P. ten Dijke

Other (performed site-directed mutagenesis for several constructs, also was involved in designing experiments and analyzing the results): P.V. Iyengar

Other (Design of mass spectrometry experiments and provided mass spectrometry facilities): A.C.O. Vertegaal

Acknowledgments

This work is supported by the Cancer Genomics Centre Netherlands, NWO (VICI grant 724.013.002 to H. Ovaas) and ERC (grant 310913 to A.C.O. Vertegaal). S. Liu is supported by the China Scholarship Council. P.V. Iyengar is supported by the European Union Horizon 2020 Research and Innovation Program with a Marie Sklodowska-Curie Individual Fellowship (786880).

The authors are grateful to Hiroshi Harada for the pcDNA4-UCHL1-myc construct and Andrew Hinck for recombinant TGFβ3. The authors thank Hans van Dam and David Baker for critical reading of the article and their lab members for valuable discussion. They are grateful to Kiki M.H. Vangangelt for the collection of sera samples in LUMC. The authors thank Marcel Smid, Fuyu Cai, and Fons J. Verbeek for bioinformatic analysis. They are grateful to Marie-Jose Goumans, Rubina Baglio, and Michael Pegtel for expert advice on exosome preparation, and Luis J. Cruz and Fabio Baldazzi for NTA analysis. The authors thank Annelies van der Laan and Lennard Voormast for confocal imaging technical assistance, Midory Thorkay for technical assistance, and Martin Rabeklin for shRNA constructs and determining of lentiviral titers.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertised in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 26, 2019; revised September 30, 2019; accepted December 16, 2019; published first December 19, 2019.

References


The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertised in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 26, 2019; revised September 30, 2019; accepted December 16, 2019; published first December 19, 2019.


Deubiquitinate Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGF β-Induced Breast Cancer Metastasis

Sijia Liu, Román González-Prieto, Mengdi Zhang, et al.


Updated version Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-19-1373

Supplementary Material Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2019/12/19/1078-0432.CCR-19-1373.DC1

Cited articles
This article cites 41 articles, 6 of which you can access for free at: http://clincancerres.aacrjournals.org/content/26/6/1460.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/26/6/1460.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/26/6/1460. Click on "Request Permissions" which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.